Acquisition expands the company’s omnichannel software suite for life sciences, product development capabilities in North America, and global life science customer base.
Iselin, NJ, April 29, 2016: Indegene (www.indegene.com), a global healthcare solutions provider, today announced the acquisition of Skura Corporation’s life science business. Skura’s SFX platform is a global leader in adaptive sales enablement technology for life science organizations and delivers next-generation sales-enablement technology, ensuring the right message reaches the right healthcare providers (HCPs) at the right time, thus, increasing sales and customer success.
Life science manufacturers, including pharmaceutical, medical device, consumer health and biotech organizations, have been accelerating the transformation of their sales, marketing, and medical functions to align faster and better with major trends like digitalization, reduction in sales forces, evolving regulatory environment, and the changing needs of HCPs. Much of the industry’s response to these changes is being driven by the adoption of newer software technologies (estimated to be ~$6 billion per annum), especially CRM, closed-loop marketing (CLM), sales enablement, campaign management, digital remote engagement, and multichannel marketing software. According to Gartner, “By 2018, digital drug launches will be the standard, with 80% of the top pharma companies announcing new products via at least five digital channels” (Source: Predicts 2016: Digital Generates Business Value Opportunities in Life Science).
On the occasion, Manish Gupta, CEO, Indegene, stated, “We see a step change in how HCPs want to engage with life sciences manufacturers, and are committed to accelerating innovation through our significant investments to address this challenging shift. We have now acquired two specialized software product offerings in this space and launched the Omnipresence for Lifesciences™ suite of technologies to address critical gaps in HCP experience and coverage from an omnichannel standpoint. We now have customers using our software products in over 50 countries across a broad range of regulatory and health system environments.”
“We’re delighted to partner with Skura as they share our transformational vision for the industry and are respected thought leaders in life sciences sales enablement. With this acquisition we’re also now looking to make Toronto our next product innovation hub in addition to Montreal, Los Angeles, and Bangalore,” said Dr. Rajesh Nair, President, Indegene.
“We see tremendous opportunity for our existing life sciences customers to leverage Indegene’s portfolio of omnichannel solutions to bring them closer to their desired business outcomes, as well as for our platforms to reach a broader audience through Indegene’s global presence and deep partnership with the industry. We’re delighted to partner with Indegene.” said Chris Skura, CEO, Skura Corporation.
Indegene enables global healthcare organizations to address complex challenges by seamlessly integrating analytics, technology, operations and medical expertise and drive better health and business outcomes. Indegene’s IP-based solutions help clients drive revenues and productivity by making transformational leaps in digitalization of customer engagement, health reform, healthcare cost reduction, and health outcomes improvement.
About Skura Corporation:
Skura is empowering the next generation of sales reps. The Skura SFX™ platform is the first to offer adaptive sales enablement, providing unprecedented visibility and insight throughout the entire sales process. Skura SFX enables sales and marketing executives to engage with customers across all channels and devices – from a single platform – providing accountability and measurement across the entire sales cycle. The Skura SFX platform offers next-generation predictive analytics, ensuring the right message reaches the right person at the right time, increasing sales and customer success.